{"id":546108,"date":"2021-06-03T23:16:01","date_gmt":"2021-06-03T23:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=546108"},"modified":"2021-06-03T23:16:01","modified_gmt":"2021-06-03T23:16:01","slug":"chronic-inflammatory-demyelinating-polyneuropathy-cidp-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_546108.html","title":{"rendered":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Chronic<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cChronic Inflammatory Demyelinating Polyneuropathy (CIDP)\u2013Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s<\/span> “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)–Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/span>” report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n

Some of the key facts of the Report:<\/span><\/strong><\/p>\n

1. The total prevalent population of CIDP in the 7MM is <\/span>44,984 in 2018 <\/span>and is expected to rise in 2030 during the study period [2018–2030]. Estimates show that the <\/span>United States <\/span>accounts for the highest cases (<\/span>approximately<\/span>65%)<\/span> of total CIDP  cases<\/span>as compared to EU5, and Japan. <\/span><\/p>\n

2. As per DelveInsight’s analysts, the overall prevalence of typical CIDP was higher as compared to atypical CIDP and is expected to increase rapidly in the coming years. In 2018, prevalent cases of typical and atypical CIDP in the US varied as <\/span>11,161 <\/span>and <\/span>10,724 <\/span>respectively. <\/span><\/p>\n

3. Among the European 5 countries, <\/span>F<\/span>rance had the highest prevalent population of CIDP with <\/span>3,716 <\/span>cases<\/span>,<\/span> followed by Germany and the UK. On the other hand, Spain had the lowest prevalent population of CIDP <\/span>1,736 cases in 2018.<\/span><\/p>\n

4. The prevalent population of CIDP in Japan had <\/span>2,065<\/span> cases in 2018. <\/span><\/p>\n

Key benefits of the report:<\/strong><\/p>\n

1.The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report covers a descriptive overview and comprehensive insight of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span><\/p>\n

2.The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report provides insights into the current and emerging therapies.<\/span><\/p>\n

3.Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/span><\/p>\n

4.The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market.<\/span><\/p>\n

Request for sample pages<\/span>: https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market<\/span><\/a><\/span>
<\/span><\/a><\/strong><\/p>\n

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Overview<\/span><\/strong><\/p>\n

Chronic inflammatory demyelinating polyneuropathy (CIDP) <\/span>is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms mainly caused by <\/span>damage to the myelin sheath <\/span>of the peripheral nerves. It is an acquired peripheral neuropathy due to an autoimmune attack of peripheral nerve myelin. Myelin is the main target of the condition, in which patients present with weakness, numbness, and sensory ataxia.  <\/span><\/p>\n

The key players involved in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market<\/a>:<\/strong><\/p>\n

 <\/p>\n

    \n
  1. \n

    Shire\/ Takeda<\/span><\/p>\n<\/li>\n

  2. \n

    UCB Biopharma<\/span><\/p>\n<\/li>\n

  3. \n

    Argenx<\/span><\/p>\n<\/li>\n

  4. \n

    Pfizer<\/span><\/p>\n<\/li>\n

  5. \n

    Momenta Pharmaceuticals<\/span><\/p>\n<\/li>\n

  6. \n

    LFB GeNeuro Pharmaceuticals<\/span><\/p>\n<\/li>\n

  7. \n

    MedDay Pharmaceuticals <\/span><\/p>\n<\/li>\n<\/ol>\n

    The launch of the emerging therapies is expected to significantly impact the  Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment scenario in the upcoming years:-<\/strong><\/p>\n

    Drug covered<\/span><\/strong><\/p>\n

      \n
    1. \n

      HyQvia<\/span><\/p>\n<\/li>\n

    2. \n

      Rozanolixizumab<\/span><\/p>\n<\/li>\n

    3. \n

      Efgartigimod <\/span><\/p>\n<\/li>\n

    4. \n

      PF-06755347<\/span><\/p>\n<\/li>\n

    5. \n

      M254 <\/span><\/p>\n<\/li>\n

    6. \n

      I10E <\/span><\/p>\n<\/li>\n

    7. \n

      GNbAC1 <\/span><\/p>\n<\/li>\n

    8. \n

      MD-1003<\/span><\/p>\n<\/li>\n<\/ol>\n

      Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market<\/span><\/a><\/span><\/strong><\/p>\n

      Table of Contents<\/span><\/strong><\/p>\n

      1. Report Introduction<\/span><\/p>\n

      2. Executive Summary<\/span><\/p>\n

      3. SWOT analysis<\/span><\/p>\n

      4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Share (%) Overview at a Glance<\/span><\/p>\n

      5. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview at a Glance<\/span><\/p>\n

      6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Disease Background and Overview<\/span><\/p>\n

      7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology and Patient Population<\/span><\/p>\n

      8. Country-Specific Patient Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) <\/span><\/p>\n

      9. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Current Treatment and Medical Practices<\/span><\/p>\n

      10. Unmet Needs<\/span><\/p>\n

      11. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Therapies<\/span><\/p>\n

      12. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook<\/span><\/p>\n

      13. Country-Wise Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis (2017–2030)<\/span><\/p>\n

      14. Market Access and Reimbursement of Therapies<\/span><\/p>\n

      15. Market drivers<\/span><\/p>\n

      16. Market barriers<\/span><\/p>\n

      17. Appendix<\/span><\/p>\n

      18. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Methodology<\/span><\/p>\n

      19. DelveInsight Capabilities<\/span><\/p>\n

      20. Disclaimer<\/span><\/p>\n

      21. About DelveInsight<\/span><\/p>\n

      Related Reports:<\/strong><\/p>\n

      Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline Insights, 2021<\/span><\/strong><\/p>\n

      “<\/span>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline Insight, 2021<\/span>” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market. A detailed picture of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape is provided, which includes the disease overview and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment guidelines.<\/span><\/p>\n

      Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Epidemiology Forecast to 2030<\/span><\/strong><\/p>\n

      DelveInsight’s ‘Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) {;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Kritika Rehani
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> 9193216187
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Las Vegas
      State:<\/strong> Nevada
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      DelveInsight Business Research LLP DelveInsight\u2019s \u201cChronic Inflammatory Demyelinating Polyneuropathy (CIDP)\u2013Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-546108","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=546108"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546108\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=546108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=546108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=546108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}